ֱ

Smartphone STEMI Detection; Sapien 3 Ultra; Novel BP Drug

— Recent developments of interest in cardiovascular medicine

MedpageToday

A smartphone ECG device picked up ST-elevation MI with high sensitivity compared with a standard 12-lead ECG, AliveCor announced.

Big money changed hands for , a novel therapy for pulmonary arterial hypertension, STAT reports.

In the ongoing saga of cancer-related compounds found in "sartans," CNN warned consumers about .

And the New York Times warned consumers that "."

with the ImpellaCP device with a 30 minute delay before reperfusion met primary safety and feasibility endpoints for reducing the severity of heart attacks in the Door to Unload pilot trial, clearing the way for a pivotal trial. (MassDevice)

The got CE mark but can't launch in Germany, because Boston Scientific got a preliminary injunction in a patent dispute. (Cath Lab Digest)

The met its endpoints in the AMBULATE pivotal trial, substantially cutting time to ambulation compared with manual compression as well as improving time to hospital discharge, patient satisfaction, and opioid use. (MDDI Online)

The for heart murmur detection algorithm using artificial intelligence algorithm, under FDA review was effective as an echocardiogram in a study. (Diagnostic and Interventional Cardiology)

The novel agent in a phase IIb trial in overweight and obese hypertensive patients. (FierceBiotech)

Long-term use of the PCSK9 inhibitor evolocumab (Repatha) reduced LDL by a of OSLER-1 trial follow-up with no neutralizing antibodies, Amgen announced.

Oscor expanded the recall on its for temporary use to encompass all remaining inventory in the field, including expired devices. (FDA)